Generic Name/Brand Name: Upadacitinib / RINVOQ Indications: Moderate-to-severe rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, and other autoimmune inflammatory conditions Dosage Form: Oral tablet Specification: 15 mg x 28 tablets
Generic Name/Brand Name: Tocilizumab/Actemra® (and biosimilars: Avtozma, Tyenne, Tofidence) Indications: Rheumatoid arthritis, Systemic juvenile idiopathic arthritis (sJIA), Cytokine release syndrome (CRS), Giant cell arteritis (GCA), COVID-19 pneumonia Dosage Form: Injection Specification: 400 mg/20 mL x 1 vial
Generic Name/Brand Name: Azathioprine Tablets/Xinyi Indications: Colorectal Cancer, Hematology, Acute and Chronic Leukemia, Acquired Hemolytic Anemia, Chronic Rheumatoid Arthritis, Hyperthyroidism Dosage Form: Tablet Specification: 50 mg x 60 tablets
On May 21, Johnson & Johnson announced that its FcRn antagonist Imaavy® (nipocalimab injection) received approval from China’s National Medical Products Administration (NMPA) for use in combination with standard therapy in adolescents aged 12 years and older and adults with…
On April 27, 2026, the National Medical Products Administration (NMPA) announced that Jiangsu Huayang Pharmaceutical’s extended-release tablets became the first generic upadacitinib approved in China after passing generic consistency evaluation. This milestone—generic upadacitinib approved in china—marks the first approved generic…
Over the past decade, autoimmune diseases have remained one of the most stable and high-growth areas in global drug innovation. From TNF-α inhibitors to IL-17/IL-23 biologics and the rise of JAK inhibitors, the field has undergone multiple waves of therapeutic…
As global drug patents continue to expire, the China Generic Drug Market Trends 2026 indicate that the industry is entering a new cycle of competition and opportunity. Around 2026, the Chinese pharmaceutical industry is approaching an important milestone. Several globally…
In the context of increasingly stringent global pharmaceutical regulations, choosing a licensed Pharmaceutical Distributor in Hong Kong with verified wholesale and export qualifications means selecting a long-term partner with regulatory compliance, cross-border execution capabilities, and supply chain stability. For regional…
As global demographic shifts, evolving disease landscapes, and rising expectations for treatment experience continue to reshape healthcare, the pharmaceutical industry is facing unprecedented opportunities and challenges. As a critical bridge between pharmaceutical innovation and clinical practice, Hong Kong DengYue Medicine…
For approximately 5.6 million patients worldwide living with progressive pulmonary fibrosis (PPF), every breath is accompanied by the relentless and irreversible scarring of their lungs. This is a fatal pulmonary disease, with nearly half of patients dying within five years…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights
